Membrane translocation and activation of GnRH receptor sensitize prostate cancer cells to radiation

References

• Bolla M, Verry C, Long J-A. 2013. High-risk prostate cancer. Curr Opin Urol. 23(4):349–354.
   PubMed Web of Science ®Google Scholar
• Bono AV, Salvadore M, Celato N. 2002. Gonadotropin-releasing hormone receptors in prostate tissue. Anal Quant Cytol Histol. 24(4):221–227.
   PubMedGoogle Scholar
• Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, et al. 2016. NCCN guidelines insights: prostate cancer early detection, version 2.2016. J Natl Compr Canc Netw. 14(5):509–519.
   PubMed Web of Science ®Google Scholar
• Castellón EA, Venegas K, Sáenz L, Contreras H, Huidobro C. 2005. Secretion of prostatic specific antigen, proliferative activity and androgen response in epithelial-stromal co-cultures from human prostate carcinoma. Int J Androl. 28(1):39–46.
   PubMed Web of Science ®Google Scholar
• Castellón E, Clementi M, Hitschfeld C, Sánchez C, Benítez D, Sáenz L, Contreras H, Huidobro C. 2006. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest. 24(3):261–268.
   PubMed Web of Science ®Google Scholar
• Clementi M, Sánchez C, Benitez D. a, Contreras HR, Huidobro C, Cabezas J, Acevedo C, Castellón E. a. 2009. Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate. 69(10):1025–1033.
   PubMed Web of Science ®Google Scholar
• Conn PM, Janovick JA, Brothers SP, Knollman PE. 2006. 'Effective inefficiency': cellular control of protein trafficking as a mechanism of post-translational regulation”. J Endocrinol. 190(1):13–16.
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Chen M-H, Renshaw AA, Loffredo M, Kantoff PW. 2008. Androgen suppression and radiation vs radiation alone for prostate cancer. JAMA. 299(3):289–295.
   PubMed Web of Science ®Google Scholar
• Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, et al. 2011. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 12(5):451–459.
   PubMed Web of Science ®Google Scholar
• Guzmán C, Bagga M, Kaur A, Westermarck J, Abankwa D. 2014. ColonyArea: an ImageJ plugin to automatically quantify colony formation in Clonogenic Assays.Rota R, editor. PLoS One. 9(3):e92444.
   PubMed Web of Science ®Google Scholar
• Harris WP, Mostaghel EA, Nelson PS, Montgomery B. 2009. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 6(2):76–85.
   PubMedGoogle Scholar
• Hashimoto Y, Ishii Y, Kono S, Izumi S, Iizuka J, Hiroi A, Karasawa K. 2017. Intensity-modulated radiation therapy for small cell carcinoma of the prostate: a case report. Rep Pract Oncol Radiother. 22(5):349–353.
   PubMedGoogle Scholar
• Hinerman-Mulroy A, Merrick GS, Butler WM, Wallner KE, Allen Z, Adamovich E. 2004. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 59(5):1367–1382.
   PubMed Web of Science ®Google Scholar
• Huggins C. 1941. Studies on prostatic cancer. Arch Surg. 43(2):209.
   Google Scholar
• Janovick JA, Maya-Nunez G, Conn PM. 2002. Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J Clin Endocrinol Metab. 87(7):3255–3262.
   PubMed Web of Science ®Google Scholar
• Keyes M, Merrick G, Frank SJ, Grimm P, Zelefsky MJ. 2017. American brachytherapy society task group report: use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review. Brachytherapy. 16(2):245–265.
   PubMed Web of Science ®Google Scholar
• Limonta P, Moretti RM, Marelli MM, Dondi D, Parenti M, Motta M. 1999. The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway 1. Endocrinology. 140(11):5250–5256.
   PubMed Web of Science ®Google Scholar
• Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N. 2017. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost f. Int J Radiat Oncol Biol Phys. 98(2):275–285.
   PubMed Web of Science ®Google Scholar
• Mottet N, Bastian PJ, Bellmunt J, Bergh RVD, Bolla M, Casteren NV, Cornford P, Joniau S, Mason MD, Matveev V, et al. 2015. Guidelines on prostate cancer. http://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-Cancer-2015-v2.pdf.
   Google Scholar
• Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, et al. 2019. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 393(10185):2051–2058.
   PubMed Web of Science ®Google Scholar
• Pollack A, Hanlon A, Horwitz EM, Feigenberg S, Uzzo RG, Price RA. 2003. Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. World J Urol. 21(4):200–208.
   PubMed Web of Science ®Google Scholar
• Pollack A, Salem N, Ashoori F, Hachem P, Sangha M, von Eschenbach AC, Meistrich ML. 2001. Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys. 51(4):1002–1007.
   PubMed Web of Science ®Google Scholar
• Rao A, Vapiwala N, Schaeffer EM, Ryan CJ. 2019. Oligometastatic prostate cancer: a shrinking subset or an opportunity for cure? Am Soc Clin Oncol Educ Book. 39:309–320.
   PubMedGoogle Scholar
• Sánchez CA, Mercado AJ, Contreras HR, Cabezas JC, Huidobro CC, Castellón EA. 2012. E a. 2012. Pharmacoperone IN3 enhances the apoptotic effect of leuprolide in prostate cancer cells by increasing the gonadotropin-releasing hormone receptor in the cell membrane. Anticancer Drugs. 23(9):959–969.
   PubMed Web of Science ®Google Scholar
• Sánchez C, Mendoza P, Contreras HR, Vergara J, McCubrey JA, Huidobro C, Castellón EA. 2009. Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate. 69(13):1448–1459.
   PubMed Web of Science ®Google Scholar
• Schulz RJ, Kagan AR. 2011. Dose escalation in the radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys. 80(5):1289–1291.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. 2016. Cancer statistics, 2016. CA Cancer J Clin. 66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Szabó J, Bartók K, Krenács T, Szepesváry Z, Szende B. 2009. GnRH receptor and androgen receptor status and outcome of advanced prostate carcinomas. Anticancer Res. 29(2):681–684.
   PubMed Web of Science ®Google Scholar
• Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang C-Z, Huang J. 2011. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate. 71(15):1668–1679.
   PubMed Web of Science ®Google Scholar
• Ulloa-Aguirre A, Janovick JA, Miranda AL, Conn PM. 2006. G-protein-coupled receptor trafficking: understanding the chemical basis of health and disease. ACS Chem Biol. 1(10):631–638.
   PubMed Web of Science ®Google Scholar
• Wu C-T, Chen W-C, Liao S-K, Hsu C-L, Lee K-D, Chen M-F. 2007. The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy. Endocr Relat Cancer. 14(3):633–643.
   PubMed Web of Science ®Google Scholar
• Xie B-X, Zhang H, Yu L, Wang J, Pang B, Wu R-Q, Qian X-L, Li S-H, Shi Q-G, Wang L-L, et al. 2010. The radiation response of androgen-refractory prostate cancer cell line C4-2 derived from androgen-sensitive cell line LNCaP. Asian J Androl. 12(3):405–414.
   PubMed Web of Science ®Google Scholar
• Zietman AL, Prince EA, Nakfoor BM, Park JJ. 1997. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys. 38(5):1067–1070.
   PubMed Web of Science ®Google Scholar